SCHEMBL3079986

SCHEMBL3079986

CON1CCC(c2ccc(N)c(C3=CCCCC3)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 10/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC2 Q92769 2/20 0.40
CSF1R P07333 13/20 0.39
CYP2C19 P33261 2/20 0.39
NTRK1 P04629 3/20 0.37
LCK P06239 3/20 0.37
AXL P30530 3/20 0.37
FLT3 P36888 3/20 0.37
BMPR1B O00238 2/20 0.36
PLK4 O00444 2/20 0.36
STK25 O00506 2/20 0.36
RIOK3 O14730 2/20 0.36
CHEK1 O14757 2/20 0.36
GAK O14976 2/20 0.36
DCLK1 O15075 2/20 0.36
MUSK O15146 2/20 0.36
EPHB6 O15197 2/20 0.36
PDPK1 O15530 2/20 0.36
MAP3K13 O43283 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3093703 0.90 CSF1R (0.43) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL25541127 0.86 QDPR (0.44) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL2912716 0.84 CSF1R (0.43) KITCSF1RCYP2C19NTRK1LCK
SCHEMBL14384990 0.83 KIT (0.43) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL16605567 0.82 HDAC1 (0.52) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL2916006 0.81 CSF1R (0.56) KITHDAC1HDAC2CSF1RCYP2C19
Trifluoroacetic Acid SCHEMBL3093692 0.79 CSF1R (0.42) KITCSF1RCYP2C19NTRK1LCK
SCHEMBL3087401 0.79 CSF1R (0.54) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL2907965 0.78 PDE4B (0.48) KITHDAC1HDAC2CSF1RCYP2C19
SCHEMBL2914743 0.78 CSF1R (0.49) KITHDAC1HDAC2CSF1RCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 US disclosed
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2015-04-02 US disclosed
US-8933091-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2015-01-13 US disclosed
US-8697716-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2014-04-15 US disclosed
US-20140005225-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-01-02 US disclosed
EP-2397138-B1 Aromatic amide derivatives as C-KIT kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-12-11 EP disclosed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 EP disclosed
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2008-02-28 US disclosed
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2008-02-28 US disclosed
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE JANSSEN PHARMACEUTICA NV (BE) 2008-02-28 US disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 US disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 US disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KIT 125/4885HDAC1 2652/4885HDAC2 3101/4885
US-20140005225-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 KIT 1/4885HDAC1 1480/4885HDAC2 1788/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R KIT 70/4885HDAC1 1257/4885HDAC2 2068/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KIT 125/4885HDAC1 2652/4885HDAC2 3101/4885
US-20080051402-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 KIT 1/4885HDAC1 1480/4885HDAC2 1788/4885
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE FLT3, PLK1, PHKG1 KIT 192/4885HDAC1 1986/4885HDAC2 2500/4885
US-20150094520-A1 METHOD OF INHIBITING C-KIT KINASE KIT, CHUK, MAP3K13 KIT 1/4885HDAC1 1480/4885HDAC2 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.